This article aimed to evaluate the efficacy and safety of JAK1 inhibitors (abrocitinib and upadacitinib) in off‐label treatment of refractory inflammatory skin diseases. We retrospectively analyzed 19 patients with various immune‐mediated dermatoses, including cutaneous lichen planus, parapsoriasis, vitiligo, autoimmune bullous diseases, hypereosinophilic dermatitis, cholinergic urticaria, and vasculitis. Patients received oral abrocitinib or upadacitinib, and the dosage was adjusted according to clinical response. Results showed that most patients achieved significant improvement. Adverse events were mild and infrequent, including folliculitis, gastric discomfort, transient thrombocytopenia, and elevated transaminases, which resolved spontaneously or after dose adjustment/withdrawal. These findings suggest that JAK1 inhibitors may be effective and well‐tolerated in managing refractory off‐label ISDs. However, given the limited evidence from case series, cautious risk‐benefit assessment is warranted in clinical practice.
Zhang et al. (Thu,) studied this question.